Same principles, different regulatory force GMP and cGMP describe the same fundamental concept — the minimum quality standards for manufacturing pharmaceutical products — but they originate from different regulatory frameworks and carry a critical practical distinction. GMP (Good Manufacturing Practice) is the term used by the World Health Organization, the European Medicines Agency, and the PIC/S (Pharmaceutical Inspection Co-operation Scheme). cGMP (current Good Manufacturing Practice) is the FDA’s term, codified in 21 CFR Parts 210 and 211. The difference is not semantic. The “c” in cGMP means that compliance is measured against contemporary capabilities, not historical baselines. If a superior manufacturing control method becomes commercially established and widely adopted, the FDA expects manufacturers to adopt it — even if the regulation’s text does not explicitly require it. This is an evolving standard, not a static checklist, and the practical consequences cascade into how validated AI software, computerised systems, and process monitoring are assessed. Side-by-side comparison Dimension GMP (WHO/EU) cGMP (FDA/US) Regulatory authority WHO, EMA, national agencies FDA Legal basis WHO TRS, EudraLex Volume 4 21 CFR Parts 210, 211 Standard evolution Updated through revisions to guidance documents “Current” — expectation evolves with available technology Computerised systems EU GMP Annex 11 21 CFR Part 11, FDA CSA guidance Data integrity ALCOA+ principles (PIC/S PI 041) ALCOA principles (FDA guidance) Validation approach Traditional IQ/OQ/PQ or risk-based CSA (risk-based) or traditional Inspection framework National inspectorates, MRA agreements FDA inspections (domestic and foreign) Where the differences matter in practice For pharmaceutical companies operating in multiple markets, the practical question is not “GMP or cGMP?” but “which standard is more stringent for this specific requirement?” The answer varies by topic: Computerised systems: EU GMP Annex 11 is more prescriptive than 21 CFR Part 11 on audit trail requirements and periodic review. Annex 11 explicitly requires consideration of audit trails for all GMP-relevant changes. Part 11 focuses on electronic records and signatures but is less explicit about audit trail review processes. Software validation: FDA’s Computer Software Assurance (CSA) guidance (2022) is more progressive than current EU expectations, allowing unscripted testing and risk-proportionate assurance for lower-risk software. EU inspectorates still tend toward traditional validation approaches, though GAMP 5 Second Edition is shifting this. Process validation: Both frameworks align on lifecycle process validation (FDA’s 2011 guidance, EU GMP Annex 15), but FDA’s three-stage model (process design, process qualification, continued process verification) is more explicitly structured. Manufacturers supplying both US and EU markets apply the more demanding requirement in each area. In our experience, that often means following EU expectations for audit trail review while applying FDA’s CSA approach for software validation — combining elements from both frameworks to achieve compliance in both jurisdictions. The EU GMP Annex 11 requirements for computerised systems are particularly relevant for organisations that need to understand the European perspective on computerised system governance alongside FDA cGMP expectations. The convergence trend ICH harmonisation guidelines (particularly ICH Q8, Q9, Q10, and Q12) are gradually aligning GMP and cGMP expectations across major markets. The Pharmaceutical Inspection Co-operation Scheme harmonises inspection practices among 54 participating authorities. For most practical purposes, the core requirements are converging. The remaining differences are in regulatory emphasis, inspection style, and the pace at which new approaches (like CSA) are adopted across jurisdictions. That said, convergence is not equivalence. When the FDA updates its expectations through warning letters, untitled letters, or new guidance, the change can take effect long before an equivalent EU revision appears. Companies that treat “GMP-compliant” as automatically satisfying cGMP frequently miss this drift. What does the “current” in cGMP mean for software systems? The “current” prefix creates an evolving obligation: cGMP-regulated software systems must reflect the current state of technology and industry expectations, not merely the technology available when the system was first validated. A system validated and compliant in 2015 may not meet cGMP expectations in 2025 if the industry standard has advanced significantly. This is observed pattern across our pharma manufacturing engagements rather than a benchmarked rate, but the directional pressure is unmistakable. For data integrity, the evolution is concrete. In 2010, paper-based records with manual signatures met cGMP data integrity expectations. By 2025, regulators expect electronic records with full audit trails, access controls, and automated data integrity checks. A manufacturing site still using paper batch records is technically cGMP-compliant only if it can demonstrate that paper records provide equivalent data integrity assurance to electronic systems — an increasingly difficult argument to make. For process monitoring, cGMP expectations have similarly shifted. Early cGMP required periodic manual checks of critical process parameters. Current expectations include continuous monitoring with automated alerts for out-of-specification conditions. Manufacturing sites that have not upgraded their monitoring systems face regulatory observations not because their process control is inadequate but because the technology standard has moved beyond periodic manual checks. We advise pharmaceutical clients to conduct technology currency assessments every three to five years: evaluate whether their validated systems meet current industry expectations, identify gaps, and plan remediation. The assessment typically runs two to four weeks of work and produces a prioritised remediation roadmap. For AI/ML software specifically, this is where retraining cadence, drift monitoring, and model-card documentation enter the cGMP picture — none of which are mentioned in 21 CFR Part 211 directly, but all of which are now part of what “current” means. FAQ What does GxP compliance specifically require when the software is AI/ML rather than deterministic code? AI/ML software must satisfy the same GxP principles — data integrity, validated state, access control, change management — but the validation evidence shifts. Instead of a static test protocol, you document training data lineage, model performance bounds, drift thresholds, and the human-in-the-loop controls that govern inference outputs. GAMP 5 Second Edition and the ISPE GAMP AI guidance frame this as a risk-based extension of existing CSV/CSA practice. Which GxP rules apply to AI training data, models, and inference outputs? Training data falls under data integrity rules (ALCOA+ / ALCOA): it must be attributable, legible, contemporaneous, original, and accurate, with controls against unauthorised modification. Models are treated as configured software components subject to change control. Inference outputs that feed GxP decisions (release, batch disposition, deviation classification) inherit the data integrity requirements of any other GxP record and must be reviewable and reproducible. How is a GxP-validated AI system kept compliant as the model retrains or drifts? Through a defined revalidation trigger framework. Continuous monitoring tracks input distribution and output performance against thresholds defined during initial qualification. A material drift or a planned retrain triggers a risk-assessed revalidation — typically a focused requalification rather than a full IQ/OQ/PQ rerun. The change is documented under existing change-control SOPs. Where is the boundary between GxP and non-GxP usage of AI inside a pharma manufacturing workflow? The boundary is set by impact on product quality, patient safety, or data integrity of GxP records. An AI system that classifies cleanroom particulate events feeding a batch record is GxP. The same model used in an internal engineering study to prioritise maintenance is not. The classification is documented in a system inventory and revisited whenever the use-case changes. Which GxP roles (system owner, QA, validation lead) own AI-specific risks and how is that documented? The system owner remains accountable for fitness-for-purpose. QA owns the validation and change-control posture. A new role — often called the model owner or ML validation lead — owns model-specific risks: training data quality, drift, retraining decisions. Responsibilities are documented in the validation plan and the system’s RACI, with explicit handoffs to QA at each lifecycle gate. How do ISPE’s GAMP AI guidance and the ISPE AI maturity model fit into an existing GxP programme? GAMP AI guidance extends GAMP 5 categories with AI-specific risk considerations — it slots into the existing software categorisation step rather than replacing it. The ISPE AI maturity model is a self-assessment tool for governance and capability, used to scope improvement programmes. Neither is a regulation; both are interpretive guidance that inspectors increasingly reference when evaluating how a site has addressed AI risk under existing cGMP / EU GMP rules. For the broader regulatory landscape that this comparison sits inside, see our overview of what GxP compliance actually requires for AI software in pharmaceutical manufacturing.
